Tryptamine Therapeutics Limited
TYPTF
$0.02
$0.007.14%
OTC PK
| 03/31/2025 | 12/31/2024 | 12/31/2024 | 09/30/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -60.72% | -- | -- | -- | -- |
| Gross Profit | 161.33% | -- | -- | -- | -- |
| SG&A Expenses | 34.27% | 39.55% | 39.55% | 46.84% | 1.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.56% | 85.63% | 85.63% | 65.43% | -41.91% |
| Operating Income | 53.19% | -85.63% | -85.63% | -65.43% | 41.91% |
| Income Before Tax | 55.19% | -54.31% | -54.31% | -15.08% | 29.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 55.19% | -54.31% | -54.31% | -6.36% | 29.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.19% | -54.31% | -54.31% | -6.36% | 29.88% |
| EBIT | 53.19% | -85.63% | -85.63% | -65.43% | 41.91% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 96.84% | 87.91% | 87.91% | 91.18% | 34.53% |
| Normalized Basic EPS | 98.31% | 87.72% | 87.72% | 91.03% | 34.48% |
| EPS Diluted | 96.84% | 87.91% | 87.91% | 91.18% | 34.53% |
| Normalized Diluted EPS | 98.31% | 87.72% | 87.72% | 91.03% | 34.48% |
| Average Basic Shares Outstanding | 1,574.23% | 1,123.67% | 1,123.67% | 1,123.67% | 6.97% |
| Average Diluted Shares Outstanding | 1,574.23% | 1,123.67% | 1,123.67% | 1,123.67% | 6.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |